This year, the company will complete its phase 2/3 clinical trial in Europe to treat AAT deficiency, it will start a phase 2 clinical trial in the US with the same product, and it expects to start a Phase 2 or phase 2/3 clinical trial to treat newly diagnosed type-1 Diabetes.
As Kamada's chairman Hahn founded and led Kamada from an idea to becoming a groundbreaking, leading company in its field of development, manufacture and marketing of specialty lifesaving biopharmaceuticals.
The Australian Patent Registrar has granted the Company a patent for inhaled Alpha-1 Antitrypsin.
The award was given based on the success of the Company's strategy in selling GLASSIA in the U.S. and worldwide, transforming it to an export-oriented company. The Company's exports in the first nine months of 2012 grew to $27.5 million
Kamada is the most advanced company in development of inhaled AAT drug for including for the treatment of CF.The previous phase II clinical trial showed an excellent safety and tolerability profile in addition to positive efficacy results indicating a substantial decrease in lung inflammation.
Kamada is among the fastest growing companies in Europe according to the Deloitte Technology Fast 500™ index for the year 2012. The list includes the 500 fastest growing companies in Europe, the Middle East and Africa (EMEA) in the fields of technology, media, communications, life sciences and cleantech.
The Company has announced that it is examining the possibility of a public offering of its ordinary shares in the United States and the listing thereof on a U.S. stock exchange. As of the date of this press release, the Company has not made any decision regarding the basic terms of the potential offering, including […]
Kamada presents positive results of measurements of efficacy and safety in a unique clinical trial, for the treatment of type 1 (juvenile onset) diabetes, with its Alpha-1 Antitrypsin (AAT) protein.
Revenues at $17.7 million,
Operating profit at $1.3 million.
An increase of 33% in revenues in the first 9 months of 2012 to $51 million.
An increase of 39% in Kamada's manufactured products sector revenues in the first 9 months of 2012 to approximately $30.5 million.
Annual revenues forecast of $72 million reflects continued growth and record revenues forecast for Q4 of 2012.
The AAT Protein in Kamada's Glassia Drug Shows Promise in a Series of Studies that Demonstrate Prevention of Lung Infection and Successful Organ Transplantation:
In several pre-clinical studies performed in Ben Gurion University, lead by Dr Eli Lewis, the Glassia drug by Kamada shows new therapeutic capabilities including being a potential treatment to bacterial lung infection, serving as a strog anti inflammatory agent in COPD and prevention of transplant rejection.
Furthermore, results of Glassia phase 2 study in Type 1 Diabetes (T1D) are expected to be published during the course of this month.